Nasdaq · Biotech stocks database
ALVO (Alvotech) stock: $5.87, $2.29B market cap, $316.1M cash, $3.27B EV, $2.01B fully diluted market cap. Next expected readout: Jul-27. Lead program: AVT29 (proposed aflibercept HD biosimilar) (Diabetic Macular Edema), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $316.1M |
|---|---|
| Debt | $1,299.1M |
| Net cash | -$983.0M |
| Enterprise value | $3,274.8M |
| Basic shares | 390.0M shares |
| Fully diluted shares | 342.0M shares |
| Fully diluted market cap | $2,007.3M |
| Cash per share | $0.81 |
Cash figures as of 2026-06-17. Database snapshot: 2026-09-21.
Loading ALVO daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Aug 12 - Sep 23 | AVT29 (proposed aflibercept HD biosimilar) | Phase 3 | Diabetic Macular Edema | — |
| Nov 12 - Dec 24 | AVT32-DRL_PB | Phase 1 | Melanoma | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.